# Effect of Alpelisib in Healthy Volunteers

> **NCT05733455** · PHASE1 · COMPLETED · sponsor: **Columbia University** · enrollment: 23 (actual)

## Conditions studied

- Insulin Resistance
- Hyperinsulinemia
- Dyslipidemias

## Interventions

- **DRUG:** Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)
- **DRUG:** Placebo (microcrystalline cellulose), 2 capsules
- **DEVICE:** FreeStyle Libre Pro
- **DIAGNOSTIC_TEST:** Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- **DIETARY_SUPPLEMENT:** BOOST Plus nutritional beverage

## Key facts

- **NCT ID:** NCT05733455
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-09
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733455, "Effect of Alpelisib in Healthy Volunteers". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05733455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*